ADIPOQ and metabolic syndrome: The metabolic syndrome group had significantly higher prevalence of CAD and lower levels of serum adiponectin, compared with groups without the metabolic syndrome (Figure 1; 31.3 versus 4.3%, p = 0.033, 4.5 ± 0.6 versus 6.4 ± 0.6 μg/mL, p = 0.014).